Methotrexate (MTX) is an effective, relatively safe, and low-cost treatment for children with JIA, but its use is often limited by the occurrence of so called intolerance in a significant number of patients [1, 2]. Many JIA patients receive anti-emetics as a co-medication to prevent or treat MTXintolerance. In a recent review in this journal Falvey et al. concluded: “Co-medication with anti-eme...